Hypoxia is the key. TEC-001 is a prodrug selectively activated in hypoxic environments, such as that induced by the long-known technique called trans-arterial embolization, a procedure that shuts off blood supply to tumors and thereby creates a low-oxygen, hypoxic environment. Delivered directly to the tumor bed through a tumor-feeding artery, hypoxia-activated TEC-001 then converts into free radicals that cause so-called immunogenic cell death (necrosis, as opposed to apoptosis) which enables immune cells—boosted with immunotherapy—to seek out and destroy tumor cells both locally, and throughout the body. CEO Ray Lee, M.D., Ph.D., explains.

Podden och tillhörande omslagsbild på den här sidan tillhör LifeSci Partners.com. Innehållet i podden är skapat av LifeSci Partners.com och inte av, eller tillsammans med, Poddtoppen.